

George M Shaw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3515076/publications.pdf>

Version: 2024-02-01

103
papers

22,115
citations

34016

52
h-index

28224

105
g-index

108
all docs

108
docs citations

108
times ranked

12890
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent anti-viral activity of a trisppecific HIV neutralizing antibody in SHIV-infected monkeys. <i>Cell Reports</i> , 2022, 38, 110199.	2.9	19
2	Zoonotic origin of the human malaria parasite <i>Plasmodium malariae</i> from African apes. <i>Nature Communications</i> , 2022, 13, 1868.	5.8	9
3	Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	5
4	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021, 371, .	6.0	49
5	The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection. <i>PLoS Pathogens</i> , 2021, 17, e1009257.	2.1	23
6	CD4 receptor diversity represents an ancient protection mechanism against primate lentiviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	9
7	Immune Responses and Viral Persistence in Simian/Human Immunodeficiency Virus SHIV.C.CH848-Infected Rhesus Macaques. <i>Journal of Virology</i> , 2021, 95, .	1.5	8
8	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. <i>Cell</i> , 2021, 184, 2955-2972.e25.	13.5	57
9	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention, and Cure. <i>Journal of Virology</i> , 2021, 95, .	1.5	21
10	Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , 2021, 95, e0079621.	1.5	6
11	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009736.	2.1	18
12	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
13	Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART. <i>JCI Insight</i> , 2021, 6, .	2.3	6
14	Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing. <i>PLoS ONE</i> , 2020, 15, e0235237.	1.1	6
15	SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	30
16	T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. <i>Nature Medicine</i> , 2020, 26, 932-940.	15.2	124
17	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020, 31, 107624.	2.9	43
18	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. <i>Journal of Virology</i> , 2020, 94, .	1.5	5

#	ARTICLE	IF	CITATIONS
19	Estimating the Timing of Early Simian-Human Immunodeficiency Virus Infections: a Comparison between Poisson Fitter and BEAST. MBio, 2020, 11, .	1.8	6
20	Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4 ⁺ T Cells. Journal of Virology, 2020, 95, .	1.5	23
21	Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model. MBio, 2019, 10, .	1.8	14
22	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. Cell Host and Microbe, 2019, 26, 336-346.e3.	5.1	88
23	Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology. Journal of Virology, 2019, 93, .	1.5	27
24	Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. Journal of Virology, 2019, 93, .	1.5	15
25	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. PLoS Pathogens, 2019, 15, e1007632.	2.1	20
26	CD4 receptor diversity in chimpanzees protects against SIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3229-3238.	3.3	21
27	Contribution of proteasome-catalyzed peptide <i>cis</i> -splicing to viral targeting by CD8 ⁺ T cells in HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24748-24759.	3.3	48
28	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. Immunity, 2019, 50, 241-252.e6.	6.6	153
29	Molecular Identification of Transmitted/Founder Hepatitis C Viruses and Their Progeny by Single Genome Sequencing. Methods in Molecular Biology, 2019, 1911, 139-155.	0.4	4
30	High multiplicity of infection following transplantation of hepatitis C virus- ⁺ positive organs. Journal of Clinical Investigation, 2019, 129, 3134-3139.	3.9	7
31	Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Cell Host and Microbe, 2018, 24, 717-730.e5.	5.1	78
32	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. Cell Reports, 2018, 25, 893-908.e7.	2.9	91
33	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nature Communications, 2018, 9, 1928.	5.8	83
34	Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7139-E7148.	3.3	16
35	Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E590-E599.	3.3	137
36	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. Journal of Virology, 2017, 91, .	1.5	52

#	ARTICLE	IF	CITATIONS
37	Staged induction of HIV-1 glycanâ€‘dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	212
38	Wild bonobos host geographically restricted malaria parasites including a putative new <i>Laverania</i> species. <i>Nature Communications</i> , 2017, 8, 1635.	5.8	45
39	Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. <i>Retrovirology</i> , 2017, 14, 35.	0.9	12
40	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. <i>PLoS Pathogens</i> , 2017, 13, e1006510.	2.1	63
41	Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. <i>JCI Insight</i> , 2017, 2, .	2.3	129
42	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. <i>PLoS Pathogens</i> , 2016, 12, e1005537.	2.1	51
43	Collapse of Cytolytic Potential in SIV-Specific CD8+ T Cells Following Acute SIV Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2016, 12, e1006135.	2.1	24
44	Multigenomic Delineation of <i>Plasmodium</i> Species of the <i>Laverania</i> Subgenus Infecting Wild-Living Chimpanzees and Gorillas. <i>Genome Biology and Evolution</i> , 2016, 8, 1929-1939.	1.1	38
45	Genomes of cryptic chimpanzee <i>Plasmodium</i> species reveal key evolutionary events leading to human malaria. <i>Nature Communications</i> , 2016, 7, 11078.	5.8	122
46	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016, 14, 97-111.	2.7	47
47	HIV-1 Vpu Mediates HLA-C Downregulation. <i>Cell Host and Microbe</i> , 2016, 19, 686-695.	5.1	127
48	Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4 + T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity. <i>EBioMedicine</i> , 2016, 3, 122-134.	2.7	67
49	Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection. <i>Journal of Virology</i> , 2016, 90, 8435-8453.	1.5	19
50	Envelope residue 375 substitutions in simianâ€‘human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	3.3	170
51	HIV-Host Interactions: Implications for Vaccine Design. <i>Cell Host and Microbe</i> , 2016, 19, 292-303.	5.1	143
52	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	13.5	305
53	Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. <i>Journal of Virology</i> , 2016, 90, 152-166.	1.5	17
54	Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. <i>PLoS Pathogens</i> , 2016, 12, e1005879.	2.1	18

#	ARTICLE	IF	CITATIONS
55	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. <i>Viruses</i> , 2015, 7, 5443-5475.	1.5	26
56	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	2.1	145
57	Transmitted/Founder Hepatitis C Viruses Induce Cell-Type- and Genotype-Specific Differences in Innate Signaling within the Liver. <i>MBio</i> , 2015, 6, e02510.	1.8	14
58	Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4. <i>MBio</i> , 2015, 6, e02518.	1.8	15
59	Transmitted Virus Fitness and Host T Cell Responses Collectively Define Divergent Infection Outcomes in Two HIV-1 Recipients. <i>PLoS Pathogens</i> , 2015, 11, e1004565.	2.1	44
60	Pathogen-Associated Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is Dependent on U-Core Length. <i>Journal of Virology</i> , 2015, 89, 11056-11068.	1.5	30
61	Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas. <i>MBio</i> , 2015, 6, .	1.8	25
62	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	5.1	66
63	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. <i>Virology</i> , 2015, 475, 37-45.	1.1	25
64	Cryptic Multiple HIV-1 Infection Revealed by Early, Frequent, and Deep Sampling during Acute Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A58-A58.	0.5	2
65	Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu056.	0.4	19
66	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. <i>Cell</i> , 2014, 158, 481-491.	13.5	266
67	Selection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins. <i>Cell Host and Microbe</i> , 2014, 16, 412-418.	5.1	47
68	African origin of the malaria parasite <i>Plasmodium vivax</i> . <i>Nature Communications</i> , 2014, 5, 3346.	5.8	167
69	Relative resistance of HIV-1 founder viruses to control by interferon-alpha. <i>Retrovirology</i> , 2013, 10, 146.	0.9	183
70	Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. <i>Virology</i> , 2013, 436, 33-48.	1.1	58
71	Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2013, 87, 4185-4201.	1.5	83
72	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013, 496, 469-476.	13.7	961

#	ARTICLE	IF	CITATIONS
73	Phenotypic properties of transmitted founder HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6626-6633.	3.3	379
74	Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. Journal of Clinical Investigation, 2013, 123, 380-93.	3.9	165
75	Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate. PLoS Pathogens, 2012, 8, e1002881.	2.1	139
76	Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape. PLoS Pathogens, 2012, 8, e1002721.	2.1	159
77	Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing. PLoS Pathogens, 2012, 8, e1002880.	2.1	74
78	HIV Transmission. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006965-a006965.	2.9	257
79	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. Journal of Virology, 2011, 85, 9998-10009.	1.5	393
80	An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum. Journal of Virology, 2011, 85, 7029-7036.	1.5	210
81	Wide Variation in the Multiplicity of HIV-1 Infection among Injection Drug Users. Journal of Virology, 2010, 84, 6241-6247.	1.5	189
82	Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys. Journal of Virology, 2010, 84, 10406-10412.	1.5	120
83	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathogens, 2010, 6, e1000890.	2.1	263
84	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1253-1272.	4.2	562
85	Inflammatory Genital Infections Mitigate a Severe Genetic Bottleneck in Heterosexual Transmission of Subtype A and C HIV-1. PLoS Pathogens, 2009, 5, e1000274.	2.1	298
86	HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC. PLoS Pathogens, 2009, 5, e1000414.	2.1	161
87	Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma. Journal of Virology, 2009, 83, 1240-1259.	1.5	67
88	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. Journal of Experimental Medicine, 2009, 206, 1117-1134.	4.2	295
89	Modeling sequence evolution in acute HIV-1 infection. Journal of Theoretical Biology, 2009, 261, 341-360.	0.8	162
90	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1273-1289.	4.2	684

#	ARTICLE	IF	CITATIONS
91	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7552-7557.	3.3	1,708
92	Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing. Journal of Virology, 2008, 82, 3952-3970.	1.5	540
93	Antigenic conservation and immunogenicity of the HIV coreceptor binding site. Journal of Experimental Medicine, 2005, 201, 1407-1419.	4.2	296
94	Antibody neutralization and escape by HIV-1. Nature, 2003, 422, 307-312.	13.7	2,233
95	Molecular Characterization of a Highly Divergent HIV Type 1 Isolate Obtained Early in the AIDS Epidemic from the Democratic Republic of Congo. AIDS Research and Human Retroviruses, 2001, 17, 1217-1222.	0.5	14
96	Evidence of Two Distinct Subsubtypes within the HIV-1 Subtype A Radiation. AIDS Research and Human Retroviruses, 2001, 17, 675-688.	0.5	82
97	Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Medicine, 1998, 4, 1302-1307.	15.2	985
98	Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo?. Immunological Reviews, 1998, 164, 37-51.	2.8	55
99	Antiviral pressure exerted by HIV-I-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Medicine, 1997, 3, 205-211.	15.2	1,138
100	Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 1995, 373, 117-122.	13.7	3,369
101	Major expansion of CD8+ T cells with a predominant V β 2 usage during the primary immune response to HIV. Nature, 1994, 370, 463-467.	13.7	630
102	Human infection by genetically diverse SIVSM-related HIV-2 in West Africa. Nature, 1992, 358, 495-499.	13.7	486
103	Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell, 1986, 45, 637-648.	13.5	827